In a significant advance for oncology, researchers in Siena, Italy, have reported promising results combining immunotherapy with liquid biopsy techniques to treat melanoma that has spread to the brain. This approach, which integrates real-time monitoring of tumor DNA in the blood with immune-boosting therapies, is offering new hope for patients facing one of the most challenging forms of metastatic cancer.
Melanoma, while less common than other skin cancers, is responsible for the majority of skin cancer deaths due to its high potential to metastasize. When it spreads to the brain, treatment options become particularly limited, and prognosis has historically been poor. However, recent clinical observations from the University Hospital of Siena suggest that combining checkpoint inhibitor immunotherapy with frequent liquid biopsy analysis may improve outcomes by enabling earlier detection of treatment response or resistance.
The liquid biopsy, a minimally invasive blood test, detects circulating tumor DNA (ctDNA) shed by cancer cells into the bloodstream. By tracking changes in ctDNA levels over time, clinicians can gain insights into tumor burden and molecular evolution without needing repeated surgical biopsies — especially valuable when tumors are located in sensitive areas like the brain.
In the Siena study, patients with brain metastases from melanoma received standard immunotherapy regimens, such as anti-PD-1 or anti-CTLA-4 antibodies, while undergoing serial liquid biopsy monitoring. Researchers observed that declines in ctDNA levels correlated with radiographic and clinical responses, allowing for timely adjustments in treatment strategy.
Dr. Luca Mazzarella, a medical oncologist involved in the research at the University of Siena, explained that the ability to monitor treatment effects in near real-time represents a paradigm shift. “We’re moving from assessing response every few months via imaging to potentially detecting molecular changes within weeks,” he said in a recent interview with ANSA, noting that this could allow clinicians to switch therapies earlier if resistance emerges.
The findings build on a growing body of evidence supporting liquid biopsy as a tool for precision oncology. Studies published in journals like Nature Medicine and Journal of Clinical Oncology have demonstrated its utility in melanoma, lung cancer, and colorectal cancer, particularly for tracking minimal residual disease and identifying emerging mutations that may confer resistance to targeted therapies or immunotherapy.
One of the key advantages of liquid biopsy in brain metastasis is its ability to reflect tumor dynamics across multiple sites, including those that are tricky to biopsy safely. Unlike imaging, which may lag behind biological changes, ctDNA fluctuations can precede radiographic progression by several weeks, offering a window for intervention.
Immunotherapy has transformed melanoma treatment over the past decade, with drugs like pembrolizumab and nivolumab significantly improving survival rates. However, response rates in patients with brain metastases remain lower than in those with extracranial disease, partly due to the immunosuppressive environment of the central nervous system and potential barriers to drug penetration.
By combining immunotherapy with liquid biopsy, researchers aim to identify which patients are likely to benefit early on and avoid prolonged exposure to ineffective treatments that carry immune-related side effects such as colitis, hepatitis, or endocrinopathies. This approach aligns with the broader goal of precision oncology: delivering the right treatment to the right patient at the right time.
How Liquid Biopsy Works in Cancer Monitoring
Liquid biopsy analyzes biomarkers such as ctDNA, circulating tumor cells (CTCs), or exosomes in bodily fluids, most commonly blood. In melanoma, specific genetic alterations — including mutations in BRAF, NRAS, and KIT genes — can be detected in ctDNA and used as molecular fingerprints to track tumor evolution.
When a tumor responds to treatment, ctDNA levels typically decrease. Conversely, a rise or persistence of ctDNA may indicate treatment resistance or disease progression. In some cases, liquid biopsy can detect emerging mutations not visible in the original tumor biopsy, such as BRAF splice variants or MEK alterations, which may guide subsequent therapy choices.
The technique is particularly valuable in melanoma given that of the disease’s high mutational burden and tendency to evolve under therapeutic pressure. Unlike tissue biopsies, which provide a snapshot of a single lesion at one point in time, liquid biopsy offers a more comprehensive and dynamic view of the tumor genome.
However, challenges remain. Sensitivity can be low in early-stage disease or when tumor shedding is minimal. False negatives may occur, and not all mutations are equally detectable in blood. Standardization of assays and interpretation guidelines is still ongoing across laboratories.
Despite these limitations, major cancer centers in Europe and the United States are increasingly incorporating liquid biopsy into clinical trials and, in select cases, routine care. The Siena team’s operate contributes to growing evidence that it may be especially useful in central nervous system metastases, where monitoring options are otherwise limited.
Implications for Patient Care and Future Research
For patients with melanoma brain metastases, the integration of liquid biopsy into treatment pathways could mean fewer invasive procedures, earlier detection of treatment failure, and more personalized therapy adjustments. It may also reduce anxiety by providing more frequent touchpoints between scans.
From a healthcare system perspective, while liquid biopsy adds cost, it may ultimately reduce expenses associated with ineffective treatments, hospitalizations for immune-related adverse events, or unnecessary procedures. Economic evaluations are underway to assess its long-term value.
Looking ahead, researchers in Siena are planning to expand their study to include larger cohorts and explore whether liquid biopsy can predict response to newer immunotherapy combinations, such as those pairing checkpoint inhibitors with LAG-3 or TIGIT inhibitors. They are also investigating whether specific ctDNA fragmentation patterns or methylomes could offer additional prognostic information.
Other institutions are pursuing similar lines of inquiry. At the Memorial Sloan Kettering Cancer Center in New York, a clinical trial is evaluating liquid biopsy-guided immunotherapy in melanoma patients with leptomeningeal metastases. In Germany, the German Cancer Research Center (DKFZ) is studying ctDNA dynamics in combination with neuroimaging to improve prediction models for brain metastasis progression.
The European Society for Medical Oncology (ESMO) has acknowledged the potential of liquid biopsy in melanoma management, though it currently recommends its use primarily within clinical trials or specialized centers due to variability in test performance.
What This Means for Patients and Clinicians
For individuals diagnosed with melanoma that has spread to the brain, the Siena findings represent a step toward more adaptive and responsive care. While immunotherapy alone has already improved outcomes, adding molecular monitoring may help refine treatment decisions in real time.
Clinicians are advised to consider liquid biopsy as a complementary tool — not a replacement for imaging or neurological assessment — particularly when evaluating treatment response or considering a change in therapy. Access to validated assays and expertise in interpreting results remains essential.
Patients interested in learning more about liquid biopsy or immunotherapy options for melanoma brain metastases can consult resources from authoritative organizations such as the American Cancer Society (cancer.org) or the Melanoma Research Foundation (melanoma.org). Those in Europe may refer to the European Association of Dermato-Oncology (eado.org) for guidelines and clinical trial information.
As with any emerging technology, continued validation through peer-reviewed research and real-world data collection is essential. The Siena team plans to publish their full findings in a scientific journal later this year, which will allow for broader scrutiny and potential integration into clinical guidelines.
The convergence of immunotherapy and liquid biopsy exemplifies how advances in immunology and molecular diagnostics are coming together to tackle some of the most difficult cancers. While challenges remain, the direction of progress is clear: toward smarter, more adaptive treatments that evolve alongside the disease.
We encourage readers to share their thoughts or experiences in the comments below and to spread awareness by sharing this article with others who may uncover it informative.
Keep reading